Claims

Factual · Their own work or organisation

“I have generally stayed away from biomed and medtech.”

Michael Burry, author replying in comments · December 2025 · Michael Lewis: Against the Rules Podcast (Cassandra Unchained)

Michael Burry has generally stayed away from investing in biomed and medtech.

Mixed Partly true and partly false in roughly equal measure.

The second judge would not resolve this claim; the verdict shown is the first judge's.

What would count as true or false

This is a claim about degree ('generally'). Test: how much of Burry's disclosed portfolio historically was in biomedical, biotech or medical-technology companies, based on 13F filings (2016 to 2025) and known Scion Capital holdings. True: such positions were rare and small, a small minority of positions and capital across periods. Mostly true: generally rare, with one or two notable exceptions. Mixed: such positions appeared often but were not dominant. Mostly false: biomed or medtech positions were recurring and sometimes significant. False: the sector was a frequent or major focus of his holdings.

Evidence

1. primary_doc.xml (Scion Asset Management Form 13F-HR, period 12-31-2020) U.S. Securities and Exchange Commission (EDGAR) · 16 February 2021

   “As of 12/31/20, Scion Asset Management held Pfizer, Inc. long call options, which are included in this 13F.”

2. Michael Burry's Top Current Stock Picks in 2025 - New Trader U New Trader U · 20 August 2025

   “Regeneron makes up 14 percent of Burry’s holdings and has been one of his more successful recent purchases.”

3. Michael Burry Portfolio | Most Recent Holdings & Activity MarketGenius

   “CI | The Cigna Group | 6.93% | Add 10.00% | 2023 Q1 | 27,500 | 280.60 USD | 7.72M USD”

4. Michael Burry - Scion Asset Management, LLC Portfolio Stock Holdings | Quiver Quantitative Quiver Quantitative

   “Scion Asset Management, LLC disclosed 9 stock positions in a recent SEC 13F filing. $68,138,076 of stock holdings were filed, with the largest holdings including MOH, LULU, and SLM.”

5. 0001567619-20-019679.txt U.S. Securities and Exchange Commission (EDGAR), Scion Asset Management 13F-HR · 16 November 2020 Own record

   “<nameOfIssuer>PFIZER INC</nameOfIssuer> <titleOfClass>COM</titleOfClass> <cusip>717081103</cusip> <value>15289</value>”

6. Scion Asset Management, LLC 13F Filings 13f.info

   “| Q2 2025 | 15 | 578,337 | UNH calls, REGN calls, LULU calls, META calls | 13F-HR | 8/14/2025 | 000187920225000038 |”

7. Scion Asset Management, LLC 13F Filings 13f.info

   “| Q1 2022 | 12 | 201,379 | AAPL puts, BMY, BKNG, DISCK | 13F-HR | 5/16/2022 | 000156761922010747 |”

8. Michael Burry portfolio: holdings and latest trades MEDGE Capital · 3 November 2025

   “54% of the 13F portfolio is in health care, followed by consumer discretionary at 26%.”

Reasoning

Scion's 13F filings show biopharma positions in several periods. Pfizer stock and call options appear in the 2020 filings (E5, E1), Bristol-Myers Squibb in Q1 2022 (E7), and Regeneron calls in Q2 2025 (E6). E2 says Regeneron alone made up 14 percent of holdings. E3 and E6 list health-care holdings such as Cigna and UnitedHealth calls, and E8 reports a 54% health-care weighting without saying which companies make it up. So biomed holdings recur and were sometimes large, but on this evidence they were not a dominant focus. Because the evidence covers only some quarters, how often they appeared cannot be fully measured.

Cite this claim

Michael Burry, “Michael Burry has generally stayed away from investing in biomed and medtech.” (said December 2025). Verdict: mixed. Reliability API, claim c_05d9876f0ad2, method 0.1.0+c876030c. https://epistacklabs.com/claims/c_05d9876f0ad2